Join us during IDWeek™ 2023
Gain insight on B‧R‧A‧H‧M‧S PCT's utility for informing antibiotic therapy decision
Gain insight on
B‧R‧A‧H‧M‧S PCT's utility for informing antibiotic therapy decision
Breaking evidence and insights into effective utilization and implementation of procalcitonin
When severe bacterial respiratory infections or sepsis are suspected, early intervention with appropriate antibiotic therapy is crucial to outcomes.
Procalcitonin (PCT) is a biomarker widely used to assess the risk of bacterial infection and to aid in antibiotic stewardship in patients with lower respiratory tract infections and sepsis. B·R·A·H·M·S PCT has been shown in thousands of publications to safely reduce antimicrobial use while concurrently improving clinical outcomes.
In this presentation Dr. Mansour will show his findings from ProSAVE (PROcalcitonin impact on antibiotic reduction, adverSe events and AVoidable healthcarE costs) regarding the role of PCT in decreasing length of antibiotic therapy in pneumonia patients.He will describe the clinical benefits of serial PCT testing use in antibiotic stewardship and the relative health economic value.
Dr. James A. Newton will discuss using PCT levels to guide the initiation and discontinuation of antibiotics in a variety of patient populations as presented in an expert opinion paper
Learning Objectives: Role of PCT
- Review the data from ProSAVE randomized controlled trial supporting PCT-aided antibiotic stewardship in LRTI and sepsis.
- Learn how PCT oversight is a critical component of antibiotic stewardship.
Learning Objectives: Antibiotic management
- Explore best practices for a successful PCT implementation leading to confident clinical adoption.
- Gain insight into how PCT-aided antibiotic stewardship provides proper antibiotic management in at-risk patients.
Speakers:
Michael K. Mansour, MD, PhD
Associate Professor of Medicine Harvard Medical School
Div. of Infectious Diseases Massachuetts General Hospital
James A. Newton, MD, FACP, FIDSA
Director of Antibiotic Stewardship
Medical Director of Infection Prevention, Control, & Treatment
Washington Regional Medical Center
Fayetteville, AR
Role of PCT in decreasing length of antibiotic therapy in pneumonia patients
ProSAVE: PROcalcitonin impact on antibiotic reduction, adverSe events and AVoidable healthcarE costs is a multi-centric randomized controlled clinical trial sponsored by Massachusetts General Hospital in collaboration with B·R·A·H·M·S GmbH, part of Thermo Fisher Scientific.
This study will use two study arms with 1:1 randomization to compare effectiveness and safety of antibiotic discontinuation guided by a PCT algorithm via a Stewardship Team over standard practice in hospitalized adult patients with suspected or confirmed community-acquired pneumonia.
Clinical Trials Registration: NCT04158804
Trial Sites:
Massachusetts General Hospital – Boston, MA
North Shore Medical Center – Salem, MA
Martha’s Vineyard Hospital – Oak Bluffs, MA
Emory Center – Grady Hospital – Atlanta, GA
Charlotte Hungerford Hospital – Torrington, CT
Texas Health Harris Methodist Hospital - Fort Worth, TX
Antibiotic management in at-risk patients
Consensus Statement for the Use of Procalcitonin in the Management of Infections in At-Risk Populations
A multi-disciplinary group of clinical experts from geriatrics, infectious diseases, emergency, pharmacy, and intensive care medicine convened to examine if the benefits of PCT translate into two critical patient profiles: aging populations and those with increasing morbidities. The group also wanted answer if PCT can be used to limit antibiotic exposure in patients who tend to experience both natural and medication-induced immune suppression.
Although multiple studies indicate that PCT can contribute to antibiotic reduction in elderly patients, there are gaps in the current body of literature for the elderly patient population, especially for the many co-morbidities that put the elderly at greater risk to both infections and antibiotic over-exposure. Through literature research and vigorous discourse, the group of experts explores these concepts and presents it as an expert opinion paper.
